Investigational drug · Phase 2
WGI-0301
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Advanced Hepatocellular Carcinoma (HCC), Hepato Cellular Carcinoma (HCC), Renal Cell Cancer.
Phase 2Last checked: Nov 19, 2026Latest source record: Sep 15, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
4
Any phase or sponsor naming "WGI-0301"
First trial start
2026
Jun 1, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "WGI-0301", any sponsor or status.
Conditions studied
As listed on its trial records.
- Advanced Hepatocellular Carcinoma (HCC)
- Hepato Cellular Carcinoma (HCC)
- Renal Cell Cancer
Approved drugs for the same conditions: Liver cancer (hepatocellular carcinoma) · Oncology · Kidney and urology
Largest trials
Live from ClinicalTrials.gov: studies naming "WGI-0301" as an intervention, largest first.
- Phase 2 Study of WGI-0301 Plus Nivolumab in Patients With HCC and RCCPivotal-lookingNot yet recruiting
Zhejiang Haichang Biotech Co., Ltd.Industry
NCT07494435 · 230 participants (planned) · Start Jun 1, 2026 · Primary completion Jun 1, 2028
Drug: WGI-0301; Nivolumab (240 mg) and 1 more · For: Hepato Cellular Carcinoma (HCC); Renal Cell Cancer
Sites: Shanghai, China
- A Study of WGI-0301 Plus Lenvatinib in Patients With Advanced HCCNot yet recruiting
Zhejiang Haichang Biotech Co., Ltd.Industry
NCT07540832 · 80 participants (planned) · Start Sep 2026 · Primary completion Sep 2028
Drug: WGI-0301; WGI-0301 and 1 more · For: Advanced Hepatocellular Carcinoma (HCC)
Sites: New York, New York
Zhejiang Haichang Biotech Co., Ltd.Industry
NCT06309485 · 60 participants (planned) · Start Jul 31, 2024 · Primary completion Dec 2026
Drug: WGI-0301 at MTD/RP2D dose IV infusion, QW; WGI-0301 at MTD/RP2D -1 dose IV infusion, QW and 2 more · For: Advanced Hepatocellular Carcinoma (HCC)
Sites: Shanghai, China; Changsha, China; Chengdu, China · 9 sites in all
Zhejiang Haichang Biotech Co., Ltd.Industry
NCT05267899 · 24 participants (planned) · Start Aug 1, 2022 · Primary completion Oct 15, 2024
Drug: WGI-0301 · For: Advanced Solid Tumors
Sites: Los Angeles, California; Whittier, California; Baltimore, Maryland
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Advanced Hepatocellular Carcinoma (HCC)
- SG001enlonstobart, Enlonstobart will be administrated on a 14-day cyclePhase 315 trials
CSPC Megalith Biopharmaceutical Co.,Ltd. · HER2-positive Gastric Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
- PD-1 inhibitorPhase 38 trials
BioAtla, Inc. · Advanced Solid Tumors, Gastric or Gastroesophageal Junction Adenocarcinoma, NSCLC (Advanced Non-small Cell Lung Cancer)
- AK105Phase 31 trial
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Advanced Hepatocellular Carcinoma (HCC)
- B7-H3 CAR-NKEB-G3B7-NK dual-target CAR-NK cells, Dual-target GPC3Phase 22 trials
Beijing Biotech · Advanced Hepatocellular Carcinoma (HCC), Metastatic Liver Cancer, Relapsed Neuroblastoma
- HA131Phase 21 trial
CSPC ZhongQi Pharmaceutical Technology Co., Ltd. · Advanced Hepatocellular Carcinoma (HCC)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.